Provides updated clinical guidelines for the multidisciplinary management of soft-tissue sarcomas.
Updates sarcoma care standards with multidisciplinary protocols; extends prior guidelines via Level 1 synthesis.
Soft-tissue sarcomas constitute an uncommon and heterogeneous group of tumors of mesenchymal origin. Diagnosis, treatment, and management should be performed by an expert multidisciplinary team. MRI/CT of the primary tumor and biopsy is mandatory before any treatment. Wide surgical resection with tumor-free tissue margin is the mainstay for localized disease. Radiotherapy is indicated in large, deep, high-grade tumors, or after marginal resection not suitable for re-excision. Perioperative chemotherapy should be discussed for high-risk sarcomas of the extremities and trunk-wall. In the case of oligometastatic disease, patients should be considered for local therapies. First-line treatment with anthracyclines (or in combination with ifosfamide) is the treatment of choice. Other drugs have shown activity in second-line therapy and in specific histological subtypes but options are limited and thus, a clinical trial should always be discussed.
No takes yet. Share an insight, caveat, or question.
Ferré et al. (2021) conducted a review in Soft-tissue sarcoma. Multidisciplinary management including wide surgical resection, risk-adapted radiotherapy, and systemic therapies like anthracyclines is recommended for soft-tissue sarcomas.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: